Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention

Headache

Volumn 55, Issue S2, 2015, Pages 103-122

  Lipton, Richard B ^a   Silberstein, Stephen D ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

chronic migraine; diagnosis; Episodic migraine; iontophoretic transdermal system; onabotulinumtoxinA injection; treatment

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN A; ERGOT ALKALOID; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; TRIPTAN DERIVATIVE; ACETYLCHOLINE RELEASE INHIBITOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ARTICLE; BRAIN DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG INDUCED HEADACHE; EPISODIC MIGRAINE; HUMAN; PRIORITY JOURNAL; REMISSION; SOCIAL ASPECT; TRANSCRANIAL MAGNETIC STIMULATION SYSTEM; TRANSFORMED MIGRAINE; DIFFERENTIAL DIAGNOSIS; MIGRAINE DISORDERS; SEVERITY OF ILLNESS INDEX;

ACETYLCHOLINE RELEASE INHIBITORS; BOTULINUM TOXINS, TYPE A; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGENTS; SEVERITY OF ILLNESS INDEX;

EID: 84922576114     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12505_2     Document Type: Article

References (124)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition (beta version). Cephalalgia. 2013; 33: 629-808.
2. MacGregor AE, Rosenberg JD, Kurth T,. Sex-related differences in epidemiological and clinic-based headache studies. Headache. 2011; 51: 843-859.
3. Nielsen CS, Knudsen GP, Steingrimsdottir OA,. Twin studies of pain. Clin Genet. 2012; 82: 331-340.
4. Aurora SK, Kulthia A, Barrodale PM,. Mechanism of chronic migraine. Curr Pain Headache Rep. 2011; 15: 57-63.
5. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349.
6. Estemalik E, Tepper S,. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013; 9: 709-720.
7. Stewart WF, Shecter A, Rasmussen BK,. Migraine prevalence: A review of population-based studies. Neurology. 1994; 44 (6 Suppl. 4): S17-S23.
8. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008; 48: 1157-1168.
9. Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013; 53: 1278-1299.
10. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010; 30: 599-609.
11. Vos T, Flaxman AD, Naghavie M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2163-2196.
12. Hawkins K, Wang S, Rupnow M,. Direct cost burden among insured US employees with migraine. Headache. 2008; 48: 553-563.
13. Bigal ME, Serrano D, Reed M, Lipton RB,. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71: 559-566.
14. Lanteri-Minet M, Duru G, Mudge M, Cottrell S,. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review. Cephalalgia. 2011; 31: 837-850.
15. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003; 60: 441-448.
16. Lipton RB, Amatniek JC, Ferrari MD, Gross M,. Migraine. Identifying and removing barriers to care. Neurology. 1994; 44 (Suppl. 4): S63-S68.
17. Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013; 53: 1300-1311.
18. Hepp Z, Bloudek LM, Varon SF,. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014; 20: 22-33.
19. Kung TA, Guyuron B, Cederna P,. Migraine surgery: A plastic surgery solution for refractory migraine headache. Plast Reconstr Surg. 2011; 127: 181-189.
20. Maizels M,. Clonazepam for refractory headache: Three cases illustrative of benefit and risk. Headache. 2010; 50: 650-656.
21. Vikelis M, Mitsikostas DD, Rapopport AM,. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): Review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr Dis Treat. 2012; 8: 429-434.
22. Lipton RB, Bigal ME,. Migraine and Other Headache Disorders. New York: Informa Healthcare; 2006.
23. Lipton RB,. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache. 2011; 51 (Suppl. 2): 77-83.
24. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorder. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
25. Headache Classification Committee, Olesen J, Bousser MG, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
26. Silberstein SD, Lipton RB, Dodick DW,. Operational diagnostic criteria for chronic migraine: Expert opinion. Headache. 2014; 54: 1258-1266.
27. Brasure M, Shamliyan TA, Butler ME, Taylor FR, Preventive pharmacological treatments for migraine in adults: Future research needs: Identification of future research needs from comparative effectiveness review No. 103 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). Apr. Report No.: 13-EHC046-EF. 2013.
28. Lipton R, Serrano D, Blumenfeld A, et al. Developing and validating the ID-Chronic Migraine (ID-CM) Screening tool. J Pain. 2014; 15 (4 Suppl.): S24. Poster presented at the 66th Annual Meeting of the American Academy of Neurology (AAN), April 26-May 3, 2014; Philadelphia PA. Poster 5.202.
29. Katsarava Z, Buse DC, Manack AN, Lipton RB,. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012; 16: 86-92.
30. Lipton RB,. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology. 2009; 72 (5 Suppl.): S3-S7.
31. Cheung V, Amoozegar F, Dilli E,. Medication overuse headache. Curr Neurol Neurosci Rep. 2015; 15: 509.
32. Grande R, Aaseth K, Benth J, Lundqvist C, Russell M,. Reduction in medication overuse headache after short information. The Akershus Study of Chronic Headache. Eur J Neurol. 2011; 18: 129-137.
33. Kristoffersen ES, Lundquist C,. Medication-overuse headache: Epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014; 5: 87-99.
34. Rossi P, Faroni JV, Tassorelli C, Nappi G,. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): A prospective, randomized, open-label trial. J Headache Pain. 2013; 14: 10.
35. Tassorelli C, Jensen R, Allena M, the COMOESTAS Consortium. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014; 34: 645-656.
36. Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012; 13: 615-624.
37. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010; 81: 428-432.
38. Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011; 76: 711-718.
39. Shapiro RE,. Preventive treatment of migraine. Headache. 2012; 52 (Suppl. 2): 65-69.
40. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78: 1337-1345.
41. Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: Effects of sex, income, and headache features. Headache. 2013; 53: 81-92.
42. Gilmore B, Michael M,. Treatment of acute migraine headache. Am Fam Physician. 2011; 83: 271-280.
43. Physician's Desk Reference 2014. Montvale, NJ: PDR, LLC; 2014. Available at: http://www.PDR.net (accessed November 29, 2014).
44. Robert T,. Medications approved by the FDA for treating migraine. Available at: http://www.helpforheadaches.com/articles/2012/Migraine-Medications-Approved-FDA.htm (accessed November 29, 2014). 2012.
45. Derry CJ, Derry S, Moore RA,. Sumatriptan (all routes of administration) for acute migraine attacks in adults-overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;(5): CD009108:doi: 10.1002/14651858.CD009108.pub2; May 28.
46. Amerge (naratriptan) prescribing information. Available at: https://www.gsksource.com/gskprm/htdocs/documents/AMERGE-PI-PIL.PDF (accessed November 21, 2014). 2013.
47. Axert (almotriptan) prescribing information. Available at: http://www.axert.com/sites/default/files/pdf/prescribing-information.pdf (accessed November 21, 2014). 2014.
48. Frova (frovatriptan) prescribing information. Available at: http://www.endo.com/File%20Library/Products/Prescribing%20Information/FROVA-Prescribing-Information.html (accessed November 21, 2014). 2013.
49. Imitrex (sumatriptan oral) prescribing information. Available at: https://www.gsksource.com/gskprm/htdocs/documents/IMITREX-TABLETS-PI-PIL.PDF (accessed November 21, 2014). 2013.
50. Maxalt (rizatriptan) prescribing information. Available at: http://www.merck.com/product/usa/pi-circulars/m/maxalt/maxalt-pi.pdf (accessed November 21, 2014). 2013.
51. Relpax (eletriptan HBr) prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=621 (accessed November 21, 2014). 2013.
52. Zomig (zolmitriptan) prescribing information. Available at: http://www1.astrazeneca-us.com/PI/zomig.pdf (accessed November 21, 2014). 2012.
53. Eros EJ,. Chronic migraine and medication-overuse headache. Neurology. 2006; 66: E43-E44.
54. Becker WJ,. The challenge of evidence-based migraine therapy. Cephalagia. 2000; 20 (Suppl. 2): 1-4.
55. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: Results from the second International Burden of Migraine Study (IBMS-II). Headache. 2013; 53: 644-655.
56. Lipton RB, Manack AN, Serrano D, Buse DC,. Acute treatment optimization for migraine: Results of the American Migraine Prevalence & Prevention (AMPP) Study. Headache. 2012; 52: 873.
57. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999; 159: 813-818.
58. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27: 814-823.
59. Linde M, Mulleners WM, Chronicle EP, McCrory DC,. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6): CD010610.
60. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007; 47: 170-180.
61. Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012; 78: 976-984.
62. OnabotulinumtoxinA [prescribing information]. Irvine, CA: Allergan Inc. 2014.
63. Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013; 28: 1225-1237.
64. Mauskop A, Butterbur-we no longer recommend it. New York Headache Blog; July 24, 2012. Available at: http://www.nyheadache.com/blog/butterbur-we-no-longer-recommend-it/ (accessed November 29, 2014). 2012.
65. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (Lisinopril): Randomized, placebo controlled, crossover study. BMJ. 2001; 322: 19-22.
66. Schuh-Hofer S, Flach U, Meisel A, et al. Efficacy of lisinopril in migraine prophylaxis-an open label study. Eur J Neurol. 2007; 14: 701-703.
67. Gales BJ, Bailey EK, Reed AN, Gales MA,. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother. 2010; 44: 360-366.
68. Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomized, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2013; 34: 523-532.
69. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA. 2003; 289: 65-69.
70. Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011; 51: 33-51.
71. Kalita J, Bhoi SK, Misra UK,. Amitriptyline vs divalproate in migraine prophylaxis: A randomized controlled trial. Acta Neurol Scand. 2013; 128: 65-72.
72. Linde M, Mulleners WM, Chronicle EP, McCrory DC,. Gapabentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6): CD010609.
73. Spira PJ, Beran RG, for the Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache. Neurology. 2003; 61: 1753-1759.
74. Ashkenazi A, Blumenfeld A,. OnabotulinumtoxinA for the treatment of headache. Headache. 2013; 52 (Suppl. 2): 54-61.
75. Whitcup SM, Turkel CC, DeGryse RE, Brin MF,. Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci. 2014; 1329: 67-80.
76. Nissan GR, Diamond ML,. Advances in migraine treatment. J Am Osteopath Assoc. 2005; 105 (4 Suppl. 2): 9S-15S.
77. Gracies JM, Lugassy M, Weisz DJ, et al. Botulinum toxin dilution and endplate targeting in spasticity: A double-blind controlled study. Arch Phys Med Rehabil. 2009; 90: 9-16, e12.
78. Parratte B, Tatu L, Vuillier F, et al. Intramuscular distribution of nerves in the human triceps surae muscle: Anatomical bases for treatment of spastic drop foot with botulinum toxin. Surg Radiol Anat. 2002; 24: 91-96.
79. Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia. 2014; 34: 853-869.
80. Malick A, Burstein R,. Peripheral and central sensitization during migraine. Funct Neurol. 2000; 15 (Suppl. 3): 28-35.
81. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793-803.
82. Diener HC, Dodick DW, Aurora SK, et al. on behalf of the PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-814.
83. Solomon S,. Botulinum toxin for the treatment of chronic migraine: The placebo effect. Headache. 2011; 51: 980-984.
84. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011; 51: 1358-1373.
85. Chen S,. Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments. Toxins (Basel). 2012; 4: 913-939.
86. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014; 34: 114-125.
87. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722.
88. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014; 83: 958-966.
89. Bigal ME, Walter S, Rapoport AM,. Calcitonin gene-related peptide (CGRP) and migraine current understanding and sate of development. Headache. 2013; 53: 1230-1244.
90. Villalon CM, Olesen J,. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009; 124: 309-323.
91. NIH. Safety tolerability and pharmacokinetics of ALD 403. Available at: http://www.clinicaltrials.gov/show/NCT01579383 (accessed September 19, 2014). 2013.
92. NIH. Ascending single doses of AMG 334 in healthy subjects and migraine patients. Available at: http://www.clinicaltrials.gov/show/NCT01688739 (accessed October 10, 2014). 2014.
93. NIH. Assessment of LBR-101 in chronic migraine. Available at: http://www.clinicaltrials.gov/show/NCT02021773 (accessed September 19, 2014). 2014.
94. NIH. A study of LY2951742 in participants with migraine. Available at: http://www.clinicaltrials.gov/ct2/show/NCT016259988 (accessed September 19, 2014). 2014.
95. Silberstein S,. MAP0004: Dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012; 13: 1961-1968.
96. Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: Efficacy of early and late treatments. Mayo Clin Proc. 2011; 86: 948-955.
97. Silberstein SD, Kori SH,. Dihydroergotamine: A review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013; 27: 385-394.
98. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache. 2011; 51: 507-517.
99. NIH. Efficacy and safety of intranasal ketorolac for the acute treatment of migraine. Available at: http://www.clinicaltrials.gov/show/NCT00483717 (accessed September 19, 2014). 2011.
100. NIH. T1-001 (intranasal oxytocin) for treatment of chronic migraine. Available at: http://www.clinicaltrials.gov/show/NCT01839149 (accessed September 19, 2014). 2014.
101. IntelGenx and RedHill Biopharma receive complete response letter from FDA for VersaFilm oral film product for acute migraines. February 4, 2014. Available at: http://www.fiercepharma.com/press-releases/intelgenx-and-redhill-biopharma-recieve-complete-response-letter-fda-versaf (accessed September 19, 2014). 2014.
102. 1F receptor agonist lasmiditan as a potential treatment of migraine attacks: A review of two placebo-controlled phase II trials. J Headache Pain. 2012; 13: 271-275.
103. 1F) receptor agonist LY334370 for acute migraine: A randomized controlled trial. Lancet. 2001; 358: 1230-1234.
104. Olesen J, Ashina M,. Emerging migraine treatments and drug targets. Trends Pharmacol Sci. 2011; 32: 352-359.
105. Silberstein SD,. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013; 93: 78-85.
106. NIH. A study using botulinum toxin type A as headache prophylaxis in adolescents with chronic migraine. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01662492 (accessed September 19, 2014). 2014.
107. Cao Y, Zheng OJ,. Tonabersat for migraine prophylaxis: A systematic review. Pain Physician. 2014; 17: 1-8.
108. Freeman JA, Trentman TL,. Clinical utility of implantable neurostimulation devices in the treatment of chronic migraine. Med Device (Auckl) 2013; 6: 195-201.
109. Saper JR, Dodick DW, Silberstein SD, et al. for the ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2010; 31: 271-285.
110. Silberstein SD,. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache. 1995; 35: 387-396.
111. Djupesland PG, Messina JC, Mahmoud RA,. Breath powered nasal delivery: A new route to rapid headache relief. Headache. 2013; 53 (Suppl. 2): 72-84.
112. Yu C, Gu P, Zhang W, et al. Evaluation of submicron emulsion as vehicles for rapid-onset intranasal delivery and improvement in brain targeting of zolmitriptan. Drug Deliv. 2011; 18: 578-585.
113. Tepper SJ, Chen S, Reidenbach F, Rapoport AM,. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013; 53 (Suppl. 2): 62-71.
114. Zomig nasal spray prescribing information. Available at: http://www.astrazeneca-us./com/pi/Zomignasalspray.pdf (accessed November 20, 2014). 2012.
115. Bird S, Derry S, Moore RA,. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014;(5): CD008616:doi: 10.1002/14651858.CD008616.pub2; May 21.
116. TM nasal delivery of sumatriptan powder. Headache. 2013; 53: 1323-1333.
117. Tepper SJ, Millson D,. Safety profile of the triptans. Expert Opin Drug Saf. 2003; 2: 123-132.
118. Goldstein J, Smith T, Pugach N, et al. The efficacy of transdermal sumatriptan is too low for general use-a response. Headache. 2014; 54: 172-174.
119. Sumatriptan iontophoretic transdermal system [prescribing information]. Jerusalem, Israel: Teva Pharmaceutical Industries Ltd; 2013.
120. FDA News Release. FDA allows marketing of first device to relieve migraine headache pain. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm378608.htm (accessed January 21, 2014). 2013.
121. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomized, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010; 9: 373-380.
122. Dodick DW, Schembri CT, Helmuth M, Aurora SK,. Transcranial magnetic stimulation for migraine: A safety review. Headache. 2010; 50: 1153-1163.
123. TM use in migraine. J Headache Pain. 2013; 14 (Suppl. 1): P222.
124. (R) device in headache treatment: A survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013; 14: 95.